BORTEZOMIB Side Effects

7006576-2 | Acute Myocardial Infarction, Myocardial Ischaemia
on Sep 21, 2010 Male patient from UNITED STATES , weighting 149.9 lb, was diagnosed with multiple myeloma (What is multiple myeloma?) and was treated with Bortezomib (View Usage). Patient experienced the following unwanted or unexpected effects: acute myocardial infarction, myocardial ischaemia. Bortezomib dosage: 1mg/m2 Days 1,4,8,11 Iv. During the same period patient was treated with METHYLPREDNISOLONE (60mg Days 1,4,8,11 Iv) (View Methylprednisolone Review and Methylprednisolone Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), ACYCLOVIR SODIUM (View Acyclovir Sodium Review and Acyclovir Sodium Label ), LIPITOR (View Lipitor Review and Lipitor Label ), PLAVIX (View Plavix Review and Plavix Label ), GABAPENTIN (View Gabapentin Review and Gabapentin Label ), LORAZEPAM (View Lorazepam Review and Lorazepam Label ), TOPROL XL (View Toprol-xl Review and Toprol-xl Label ). Patient was hospitalized.

6756923-1 | Abdominal Pain, Diarrhoea, Faeces Discoloured, Orthostatic Hypotension
Patient was taking Bortezomib (View Usage). Patient had the following side effects: abdominal pain (What is abdominal pain?), diarrhoea, faeces discoloured, orthostatic hypotension on Jun 03, 2010 from UNITED STATES Additional patient health information: Male patient , 63 years of age, weighting 175.3 lb, . Bortezomib dosage: 2.6 Mg Iv. During the same period patient was treated with LENALIDOMIDE (10 Mg Po) (View Lenalidomide Review and Lenalidomide Label ). Patient was hospitalized.

6744542-2 | Anaemia, Neuropathy Peripheral
Adverse event was reported on May 26, 2010 by a Male patient taking Bortezomib (View Usage) (Dosage: 1.9 Mg Once Iv) was diagnosed with neoplasm malignant and. Location: UNITED STATES , 87 years of age, After Bortezomib was administered, patient had the following side effects: anaemia, neuropathy peripheral.

6644606-8 | Ascites, Bilirubin Conjugated Increased, Blood Bilirubin Increased, Cerebral Ischaemia, Cortical Laminar Necrosis, Escherichia Bacteraemia, Hepatosplenomegaly, Hypotension, Meningitis Bacterial
on Mar 18, 2010 Male patient from UNITED STATES , 13 years of age, weighting 122.6 lb, was diagnosed with acute lymphocytic leukaemia and was treated with Bortezomib (View Usage). Patient experienced the following unwanted or unexpected effects: ascites, bilirubin conjugated increased, blood bilirubin increased, cerebral ischaemia, cortical laminar necrosis, escherichia bacteraemia, hepatosplenomegaly, hypotension, meningitis bacterial. Bortezomib dosage: 1.3mg/m2/day Day 1, 4, 8, 11 Iv. During the same period patient was treated with ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), BACTRIM (View Bactrim Review and Bactrim Label ), CETERIZINE (View Ceterizine Review and Ceterizine Label ), CIPROFLOXACIN HCL (View Ciprofloxacin Hcl Review and Ciprofloxacin Hcl Label ), COD LIVER OIL (View Cod Liver Oil Review and Cod Liver Oil Label ). Patient was hospitalized.


6635670-0 | Dehydration, Hypophagia, Hypotension, Nausea, Renal Disorder, Weight Decreased
on Mar 12, 2010 Female patient from UNITED STATES , weighting 172.2 lb, was diagnosed with neutralising antibodies and was treated with Bortezomib (View Usage). Patient had the following side effects: dehydration, hypophagia, hypotension, nausea (What is nausea?), renal disorder, weight decreased. Bortezomib dosage: 2.5 Mg 4 Doses Iv 2.6 2 Doses Iv. Patient was hospitalized.

6582563-3 | Treatment Noncompliance
Patient was taking Bortezomib (View Usage). After Bortezomib was administered, patient had the following side effects: treatment noncompliance on Feb 12, 2010 from UNITED STATES Additional patient health information: Male patient , 64 years of age, weighting 202.2 lb, was diagnosed with multiple myeloma (What is multiple myeloma?) and. Bortezomib dosage: 3.5 Mg Qweek Iv.

6527786-4 | Abdominal Discomfort
Adverse event was reported on Jan 05, 2010 by a Male patient taking Bortezomib (View Usage) (Dosage: 1.0 Mg/m2 D 1,4,8,11 Iv Push) was diagnosed with multiple myeloma (What is multiple myeloma?) and. Location: UNITED STATES , weighting 142.0 lb, Patient experienced the following unwanted or unexpected effects: abdominal discomfort. During the same period patient was treated with CYCLOPHOSPHAMIDE (3 G/m2 Once Iv) (View Cyclophosphamide Review and Cyclophosphamide Label ). Patient was hospitalized.

6527276-9 | Dehydration
on Jan 04, 2010 Female patient from UNITED STATES , 80 years of age, weighting 162.3 lb, was diagnosed with multiple myeloma (What is multiple myeloma?) and was treated with Bortezomib (View Usage). Patient had the following side effects: dehydration. Bortezomib dosage: 2.4mg D1,4,8,11 Iv (every 21 Days). During the same period patient was treated with DOXORUBICIN HCL (D1, 8 Iv (every 21 Days)) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ). Patient was hospitalized.

6504028-7 | Acidosis, Blood Culture Positive, Empyema, Febrile Neutropenia, Hypotension, Pleural Effusion, Pneumonia Necrotising, Respiratory Distress, Septic Shock
on Dec 16, 2009 Female patient from UNITED STATES , weighting 58.86 lb, was diagnosed with acute lymphocytic leukaemia recurrent and was treated with Bortezomib (View Usage). After Bortezomib was administered, patient had the following side effects: acidosis, blood culture positive, empyema, febrile neutropenia, hypotension, pleural effusion, pneumonia necrotising, respiratory distress, septic shock. Bortezomib dosage: Qs On Days 1,4, 8 + 11 Iv. During the same period patient was treated with DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), PEG ASPARAGINASE (View Peg-asparaginase Review and Peg-asparaginase Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ). Patient was hospitalized.

6479628-3 | Asthenia, Full Blood Count Decreased
Patient was taking Bortezomib (View Usage). Patient experienced the following unwanted or unexpected effects: asthenia, full blood count decreased on Dec 07, 2009 from UNITED STATES Additional patient health information: Female patient , 80 years of age, weighting 162.3 lb, was diagnosed with multiple myeloma (What is multiple myeloma?) and. Bortezomib dosage: 2.4mg D1,4,8,11 Iv (every 21 Days). During the same period patient was treated with DOXORUBICIN HCL ((28mg D 1 And 8 Iv (every 21 Days)) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ). Patient was hospitalized.

6453128-9 | Wound Dehiscence
Adverse event was reported on Nov 23, 2009 by a Male patient taking Bortezomib (View Usage) (Dosage: 1.3 Mg/m2 Day 1, 4, 8, 11 Iv) . Location: UNITED STATES , 30 years of age, weighting 239.9 lb, Patient had the following side effects: wound dehiscence. During the same period patient was treated with TIPIFARNIB 300 MG BID (300 Mg/bid 10-13-2009 To 10-20-2009) (View Tipifarnib 300 Mg Bid Review and Tipifarnib 300 Mg Bid Label ). Patient was hospitalized.

6433812-3 | Anaphylactic Reaction
on Nov 06, 2009 Female patient from UNITED STATES , 65 years of age, was diagnosed with multiple myeloma (What is multiple myeloma?) and was treated with Bortezomib (View Usage). After Bortezomib was administered, patient had the following side effects: anaphylactic reaction. Bortezomib dosage: 3 Mg Other Iv. Patient was hospitalized.

6426131-2 | Gait Disturbance, Haematoma, Platelet Count Decreased, Procedural Site Reaction, Spinal Cord Compression
on Nov 03, 2009 Male patient from UNITED STATES , 30 years of age, weighting 239.9 lb, was treated with Bortezomib (View Usage). Patient experienced the following unwanted or unexpected effects: gait disturbance, haematoma, platelet count decreased, procedural site reaction, spinal cord compression. Bortezomib dosage: 1.3 Mg/m2 Day 1, 4, 8, 11 Iv. During the same period patient was treated with TIPIFARNIB 300 MG BID (300 Mg Bid) (View Tipifarnib 300 Mg Bid Review and Tipifarnib 300 Mg Bid Label ). Patient was hospitalized.

6425967-1 | Axonal Neuropathy, Peripheral Sensorimotor Neuropathy
Patient was taking Bortezomib (View Usage). Patient had the following side effects: axonal neuropathy, peripheral sensorimotor neuropathy on Nov 03, 2009 from UNITED STATES Additional patient health information: Male patient , 71 years of age, weighting 147.7 lb, . Bortezomib dosage: 2.4 Mg Prn Iv. Patient was hospitalized.

6413312-7 | Abdominal Pain Lower, Abscess Bacterial, Bacterial Infection, Blood Culture Positive, Graft Complication, Graft Infection, Medical Device Complication, Nausea, Pyrexia
Adverse event was reported on Oct 22, 2009 by a Female patient taking Bortezomib (View Usage) (Dosage: 1.9 Mg 7 Doses Iv, Bid X 2 Wks With One Wk Rest X 4 Weeks) was diagnosed with transplant and. Location: UNITED STATES , weighting 114.6 lb, After Bortezomib was administered, patient had the following side effects: abdominal pain lower, abscess bacterial, bacterial infection (What is bacterial infection?), blood culture positive, graft complication, graft infection, medical device complication, nausea (What is nausea?), pyrexia. Patient was hospitalized.

6342161-3 | Bacterial Infection, Blood Disorder, Blood Pressure Fluctuation, Cardiac Arrest, Chills, Hypertension, Hypotension, Hypothermia, Inappropriate Antidiuretic Hormone Secretion
on Sep 04, 2009 Female patient from UNITED STATES , weighting 21.16 lb, was diagnosed with acute lymphocytic leukaemia recurrent and was treated with Bortezomib (View Usage). Patient experienced the following unwanted or unexpected effects: bacterial infection (What is bacterial infection?), blood disorder, blood pressure fluctuation, cardiac arrest (What is cardiac arrest?), chills, hypertension, hypotension, hypothermia (What is hypothermia?), inappropriate antidiuretic hormone secretion. Bortezomib dosage: 1.3mg/m2/day Days 1, 4, 8, And 11 Iv. During the same period patient was treated with PANTOPRAZOLE SODIUM (View Pantoprazole Sodium Review and Pantoprazole Sodium Label ), KYTRIL (View Kytril Review and Kytril Label ), IMIPENEM AND CILASTATIN SODIUM (View Imipenem And Cilastatin Sodium Review and Imipenem And Cilastatin Sodium Label ), MICAFUNGIN (View Micafungin Review and Micafungin Label ), GANCICLOVIR (View Ganciclovir Review and Ganciclovir Label ), ENALAPRIL MALEATE (View Enalapril Maleate Review and Enalapril Maleate Label ), LABELATOL (View Labelatol Review and Labelatol Label ), MORPHINE (View Morphine Review and Morphine Label ). Patient was hospitalized.

6199886-2 | Convulsion, Eye Pain, Fungal Skin Infection, Headache, Mucormycosis, Muscle Disorder, Reversible Posterior Leukoencephalopathy Syndrome, Sinusitis Fungal, Swelling
on May 20, 2009 Male patient from UNITED STATES , 13 years of age, weighting 81.35 lb, was diagnosed with leukaemia recurrent and was treated with Bortezomib (View Usage). Patient had the following side effects: convulsion, eye pain, fungal skin infection, headache (What is headache?), mucormycosis, muscle disorder (What is muscle disorder?), reversible posterior leukoencephalopathy syndrome, sinusitis fungal, swelling. Bortezomib dosage: 1.3mg/m2/day Days 1, 4, 8, 11 Iv. During the same period patient was treated with CEFEPIME (View Cefepime Review and Cefepime Label ), FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ). Patient was hospitalized.

5968754-0 | Asthenia, Dyskinesia, Dysstasia, Hypoaesthesia, Hyponatraemia, Neuralgia, Paraesthesia, Peripheral Sensory Neuropathy
Patient was taking Bortezomib (View Usage). After Bortezomib was administered, patient had the following side effects: asthenia, dyskinesia, dysstasia, hypoaesthesia, hyponatraemia, neuralgia, paraesthesia, peripheral sensory neuropathy on Nov 25, 2008 from UNITED STATES Additional patient health information: Male patient , weighting 119.7 lb, was diagnosed with acute lymphocytic leukaemia and. Bortezomib dosage: 1.3mg/m2/day Days 1, 4, 8, 11 Iv (4 Doses). During the same period patient was treated with BACTRIM (View Bactrim Review and Bactrim Label ), FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ), MEROPENEM (View Meropenem Review and Meropenem Label ), PANTOPRAZOLE SODIUM (View Pantoprazole Sodium Review and Pantoprazole Sodium Label ), ZOFRAN (View Zofran Review and Zofran Label ). Patient was hospitalized.

5951081-5 | Genital Abscess, Vulvovaginal Pain
Adverse event was reported on Nov 11, 2008 by a Female patient taking Bortezomib (View Usage) (Dosage: 2.2 Mg Once Iv 2.1 Mg Twice Iv) was diagnosed with inhibiting antibodies and. Location: UNITED STATES , weighting 130.5 lb, Patient experienced the following unwanted or unexpected effects: genital abscess, vulvovaginal pain. Patient was hospitalized.

5940157-4 | Abdominal Pain, Aeromona Infection, Atelectasis, Blood Culture Positive, Blood Pressure Decreased, Body Temperature Increased, Chest Pain, Chills, Collapse Of Lung
on Oct 31, 2008 Female patient from UNITED STATES , child 8 years of age, weighting 70.77 lb, was diagnosed with acute lymphocytic leukaemia and was treated with Bortezomib (View Usage). Patient had the following side effects: abdominal pain (What is abdominal pain?), aeromona infection, atelectasis, blood culture positive, blood pressure decreased, body temperature increased, chest pain (What is chest pain?), chills, collapse of lung. Bortezomib dosage: 1.3mg/m2/day Days 1, 4, 8, 11 Iv. During the same period patient was treated with DAPSONE (View Dapsone Review and Dapsone Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), DOCUSATE (View Docusate Review and Docusate Label ), FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ), MIRALAX (View Miralax Review and Miralax Label ), ONDANSETRON (View Ondansetron Review and Ondansetron Label ). Patient was hospitalized.

5931248-2 | Dehydration, Hyponatraemia, Hypophagia, Nausea
on Oct 24, 2008 Male patient from UNITED STATES , weighting 154.3 lb, was diagnosed with mantle cell lymphoma and was treated with Bortezomib (View Usage). After Bortezomib was administered, patient had the following side effects: dehydration, hyponatraemia, hypophagia, nausea (What is nausea?). Bortezomib dosage: 2.5 X 2 Iv. During the same period patient was treated with RITUXIMAB (715 X 1 Iv) (View Rituximab Review and Rituximab Label ), CYCLOPHOSPHAMIDE (570 Mg X 6 Iv) (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HCL (48 Mg X 2 Iv) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINCRISTINE (2 Mg X 1 Iv) (View Vincristine Review and Vincristine Label ), DEXAMETHASONE TAB (40 Mg X 4 Po) (View Dexamethasone Tab Review and Dexamethasone Tab Label ). Patient was hospitalized.

5878683-9 | Blood Pressure Decreased, Dyspnoea, Haematuria, Heart Rate Increased, Lethargy, Multi-organ Failure, Oxygen Saturation Decreased, Pancytopenia, Rhabdomyolysis
Patient was taking Bortezomib (View Usage). Patient experienced the following unwanted or unexpected effects: blood pressure decreased, dyspnoea, haematuria, heart rate increased, lethargy, multi-organ failure, oxygen saturation decreased, pancytopenia, rhabdomyolysis on Sep 10, 2008 from UNITED STATES Additional patient health information: Male patient , weighting 257.9 lb, was diagnosed with multiple myeloma (What is multiple myeloma?) and. Bortezomib dosage: 2.4 Mg Twice Per Week Iv Drip. During the same period patient was treated with THALIDOMIDE (50mg Daily Po) (View Thalidomide Review and Thalidomide Label ).

5841096-X | Pyrexia
Adverse event was reported on Aug 11, 2008 by a Female patient taking Bortezomib (View Usage) (Dosage: 2.3mg Once Iv) was diagnosed with hla marker study positive and. Location: UNITED STATES , weighting 137.3 lb, Patient had the following side effects: pyrexia. Patient was hospitalized.

5822415-7 | Bacillus Infection, Catheter Related Infection, Neutrophilia
on Jul 23, 2008 Male patient from UNITED STATES , child 6 years of age, weighting 51.15 lb, was diagnosed with neuroblastoma (What is neuroblastoma?) and was treated with Bortezomib (View Usage). After Bortezomib was administered, patient had the following side effects: bacillus infection, catheter related infection, neutrophilia. Bortezomib dosage: . During the same period patient was treated with IRINOTECAN HCL (View Irinotecan Hcl Review and Irinotecan Hcl Label ), CEFPODOXIME PROXETIL (View Cefpodoxime Proxetil Review and Cefpodoxime Proxetil Label ), HEPARIN (View Heparin Review and Heparin Label ), IMODIUM (View Imodium Review and Imodium Label ), OXYCODON (View Oxycodon Review and Oxycodon Label ), POTASSIUM IODIDE (View Potassium Iodide Review and Potassium Iodide Label ), PRILOSEC (View Prilosec Review and Prilosec Label ), ZOFRAN (View Zofran Review and Zofran Label ). Patient was hospitalized.

5819093-X | Bacillus Infection, Blood Culture Positive, Catheter Related Infection, Pyrexia
on Jul 21, 2008 Male patient from UNITED STATES , weighting 50.30 lb, was diagnosed with neuroblastoma (What is neuroblastoma?) and was treated with Bortezomib (View Usage). Patient experienced the following unwanted or unexpected effects: bacillus infection, blood culture positive, catheter related infection, pyrexia. Bortezomib dosage: 1.04 Mg D1, 4, 8, 11. During the same period patient was treated with IRINOTECAN HCL (30 Mg D 1-5 Of 21d Cycl) (View Irinotecan Hcl Review and Irinotecan Hcl Label ). Patient was hospitalized.

5809716-3 | Neutropenia, Pyrexia
Patient was taking Bortezomib (View Usage). Patient had the following side effects: neutropenia, pyrexia on Jul 11, 2008 from UNITED STATES Additional patient health information: Male patient , child 6 years of age, weighting 51.15 lb, was diagnosed with neuroblastoma (What is neuroblastoma?) and. Bortezomib dosage: 1.04mg, D1,4,8,11, Iv May + June, 4days/month. During the same period patient was treated with IRINOTECAN HCL (30mg D1-5 Cycle, Iv May + June, 5 Days/month) (View Irinotecan Hcl Review and Irinotecan Hcl Label ), CEFPODOXIME PROXETIL (View Cefpodoxime Proxetil Review and Cefpodoxime Proxetil Label ), HEPARIN (View Heparin Review and Heparin Label ), IMODIUM (View Imodium Review and Imodium Label ), OXYCODON (View Oxycodon Review and Oxycodon Label ), POTASSIUM IODIDE (View Potassium Iodide Review and Potassium Iodide Label ), PRILOSEC (View Prilosec Review and Prilosec Label ), ZOFRAN (View Zofran Review and Zofran Label ). Patient was hospitalized.

5800630-6 | Febrile Neutropenia, Infection, Platelet Count Decreased, Pneumonia, White Blood Cell Count Increased
Adverse event was reported on Jul 02, 2008 by a Male patient taking Bortezomib (View Usage) (Dosage: 5.4 Mg D1+4 Iv) was diagnosed with mantle cell lymphoma and. Location: UNITED STATES , 59 years of age, weighting 198.0 lb, After Bortezomib was administered, patient had the following side effects: febrile neutropenia, infection (What is infection?), platelet count decreased, pneumonia (What is pneumonia?), white blood cell count increased. During the same period patient was treated with CYCLOPHOSPHAMIDE (3780 Mg D1, 2,3 Iv) (View Cyclophosphamide Review and Cyclophosphamide Label ), RITUXAN 790MG IV DAY 1 (790mg Iv Day 1) (View Rituxan 790mg Iv Day 1 Review and Rituxan 790mg Iv Day 1 Label ), DOXORUBICIN HCL (106mg D1-2 Civ) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), DEXAMETHASONE (160mg Po) (View Dexamethasone Review and Dexamethasone Label ), VINCRISTINE (1mg) (View Vincristine Review and Vincristine Label ). Patient was hospitalized.

5793070-X | Bacillus Infection, Blood Culture Positive, Pyrexia
on Jun 26, 2008 Male patient from UNITED STATES , weighting 50.30 lb, was diagnosed with neuroblastoma (What is neuroblastoma?) and was treated with Bortezomib (View Usage). Patient experienced the following unwanted or unexpected effects: bacillus infection, blood culture positive, pyrexia. Bortezomib dosage: 1.04 Mg D1, 4, 8, 11 Iv. During the same period patient was treated with IRINOTECAN (30 Mg D1-5 Of 21d Cycl Iv) (View Irinotecan Review and Irinotecan Label ). Patient was hospitalized.

5782965-9 | Diarrhoea, Ileus Paralytic, Pyrexia, Vomiting
on Jun 19, 2008 Male patient from UNITED STATES , weighting 170.0 lb, was diagnosed with non-hodgkin's lymphoma and was treated with Bortezomib (View Usage). Patient had the following side effects: diarrhoea, ileus paralytic, pyrexia, vomiting. Bortezomib dosage: 1.3 Mg/m3 Day 1, 4, 8, 11 Iv. During the same period patient was treated with BENDAMUSTINE (View Bendamustine Review and Bendamustine Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ). Patient was hospitalized.

5758380-0 | Blood Creatinine Increased, Renal Injury
Patient was taking Bortezomib (View Usage). After Bortezomib was administered, patient had the following side effects: blood creatinine increased, renal injury on Jun 02, 2008 from UNITED STATES Additional patient health information: Male patient , 74 years of age, weighting 155.9 lb, was diagnosed with mantle cell lymphoma and. Bortezomib dosage: 2.4mg D1+4 Iv. During the same period patient was treated with CYCLOPHOSPHAMIDE (555 Mg D1,2,3 Iv) (View Cyclophosphamide Review and Cyclophosphamide Label ), RITUXAN (695 Mg Iv Day 1) (View Rituxan Review and Rituxan Label ), DOXORUBICIN HCL (46 Mg D1-2 Civ) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), DEXAMETHASONE TAB (40mg Po 1-4, Iv) (View Dexamethasone Tab Review and Dexamethasone Tab Label ), VINCRISTINE (1mg D3 Iv) (View Vincristine Review and Vincristine Label ). Patient was hospitalized.

5749576-2 | Cardiac Failure, Dyspnoea At Rest, Dyspnoea Exertional, Ejection Fraction Decreased, Pleural Effusion, Pneumonia, Pulmonary Oedema, Pyrexia
Adverse event was reported on May 20, 2008 by a Male patient taking Bortezomib (View Usage) (Dosage: 2.4mg D1+4 Iv) was diagnosed with mantle cell lymphoma and. Location: UNITED STATES , 74 years of age, weighting 167.0 lb, Patient experienced the following unwanted or unexpected effects: cardiac failure, dyspnoea at rest, dyspnoea exertional, ejection fraction decreased, pleural effusion, pneumonia (What is pneumonia?), pulmonary oedema, pyrexia. During the same period patient was treated with CYCLOPHOSPHAMIDE (555 Mg D1,2,3 Iv) (View Cyclophosphamide Review and Cyclophosphamide Label ), RITUXAN 695MG IV DAY 1 (695mg Iv Day 1) (View Rituxan 695mg Iv Day 1 Review and Rituxan 695mg Iv Day 1 Label ), DOXORUBICIN HCL (46mg D1-2 Civ) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), DEXAMETHASONE (40mg Po 1-4) (View Dexamethasone Review and Dexamethasone Label ), VINCRISTINE (1mg D3 Iv) (View Vincristine Review and Vincristine Label ). Patient was hospitalized.

5731776-9 | Alpha Haemolytic Streptococcal Infection, Bacteraemia, Herpes Simplex
on May 06, 2008 Female patient from UNITED STATES , weighting 100.5 lb, was diagnosed with acute lymphocytic leukaemia and was treated with Bortezomib (View Usage). Patient had the following side effects: alpha haemolytic streptococcal infection, bacteraemia, herpes simplex (What is herpes simplex?). Bortezomib dosage: 1.3mg/m2/day Days 1, 4, 8, 11 Iv. During the same period patient was treated with FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ), NORETHINDRONE (View Norethindrone Review and Norethindrone Label ), CETIRIZINE HCL (View Cetirizine Hcl Review and Cetirizine Hcl Label ), ESOMEPRAZOLE (View Esomeprazole Review and Esomeprazole Label ), LEVOFLOXACIN (View Levofloxacin Review and Levofloxacin Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), DIPHENHYDRAMINE HCL (View Diphenhydramine Hcl Review and Diphenhydramine Hcl Label ), BACTRIM (View Bactrim Review and Bactrim Label ). Patient was hospitalized.

5723400-6 | Constipation, Decreased Appetite, Epistaxis, Nasopharyngitis, Thrombocytopenia
on Apr 29, 2008 Female patient from UNITED STATES , 69 years of age, weighting 225.0 lb, was diagnosed with multiple myeloma (What is multiple myeloma?) and was treated with Bortezomib (View Usage). After Bortezomib was administered, patient had the following side effects: constipation (What is constipation?), decreased appetite, epistaxis, nasopharyngitis, thrombocytopenia. Bortezomib dosage: 2.6mg Other Iv. Patient was hospitalized.

5677214-6 | Aortic Thrombosis, Platelet Count Increased
Patient was taking Bortezomib (View Usage). Patient experienced the following unwanted or unexpected effects: aortic thrombosis, platelet count increased on Mar 21, 2008 from UNITED STATES Additional patient health information: Male patient , weighting 143.3 lb, was diagnosed with lung neoplasm malignant and. Bortezomib dosage: 2.8 Mg Wk 1 + 2 Of 3 Wks Iv Bolus. During the same period patient was treated with BEVACIZUMAB (975 Mg Q 3 Weeks Iv Drip) (View Bevacizumab Review and Bevacizumab Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), NEXIUM (View Nexium Review and Nexium Label ), COUMADIN (View Coumadin Review and Coumadin Label ), ZOFRAN (View Zofran Review and Zofran Label ), SPIRIVA (View Spiriva Review and Spiriva Label ), MIRACLE MOUTHWASH (View Miracle Mouthwash Review and Miracle Mouthwash Label ), ADVAIR DISKUS 100/50 (View Advair Diskus 100/50 Review and Advair Diskus 100/50 Label ). Patient was hospitalized.

5674896-X | Gallbladder Disorder, Hepatic Infection Fungal, Mucormycosis
Adverse event was reported on Mar 19, 2008 by a Male patient taking Bortezomib (View Usage) (Dosage: 2.4mg Iv) was diagnosed with t-cell lymphoma recurrent and. Location: UNITED STATES , weighting 156.5 lb, Patient had the following side effects: gallbladder disorder, hepatic infection fungal, mucormycosis.

5624263-X | Catheter Related Complication, Deep Vein Thrombosis, Embolism
on Feb 08, 2008 Male patient from UNITED STATES , 48 years of age, weighting 282.2 lb, was diagnosed with mantle cell lymphoma and was treated with Bortezomib (View Usage). After Bortezomib was administered, patient had the following side effects: catheter related complication, deep vein thrombosis (What is deep vein thrombosis?), embolism. Bortezomib dosage: B=3.1 Mg; B=d1+4; Iv. During the same period patient was treated with CYCLOPHOSPHAMIDE (C=720 Mg; C=d1,2,3; Iv) (View Cyclophosphamide Review and Cyclophosphamide Label ), RITUXAN (View Rituxan Review and Rituxan Label ), DOXORUBICIN HCL (Dox=60mg;dox=d1-2;civ) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), DEXAMETHASONE (Dex=1-4) (View Dexamethasone Review and Dexamethasone Label ), VINCRISTINE (Vcr=1mg D3; Iv) (View Vincristine Review and Vincristine Label ).

5608920-7 | Abdominal Pain, Diarrhoea, Nausea
on Jan 29, 2008 Male patient from UNITED STATES , 60 years of age, weighting 116.4 lb, was diagnosed with renal cell carcinoma and was treated with Bortezomib (View Usage). Patient experienced the following unwanted or unexpected effects: abdominal pain (What is abdominal pain?), diarrhoea, nausea (What is nausea?). Bortezomib dosage: 1.6 Mg/m2 Days 1+8. During the same period patient was treated with BEVACIZUMAB (15 Mg/kg Day 1) (View Bevacizumab Review and Bevacizumab Label ), ATENOLOL (View Atenolol Review and Atenolol Label ). Patient was hospitalized.

5598138-9 | Abdominal Pain, Blood Creatinine Increased
Patient was taking Bortezomib (View Usage). Patient had the following side effects: abdominal pain (What is abdominal pain?), blood creatinine increased on Jan 17, 2008 from UNITED STATES Additional patient health information: Male patient , 60 years of age, weighting 116.4 lb, was diagnosed with renal cell carcinoma and. Bortezomib dosage: 1.6 Mg/m2 Days 1+8 Iv. During the same period patient was treated with BEVACIZUMAB (15 Mg/kg Day 1 Iv) (View Bevacizumab Review and Bevacizumab Label ), ATENOLOL (View Atenolol Review and Atenolol Label ). Patient was hospitalized.

5578808-9 | Pulmonary Embolism
Adverse event was reported on Dec 28, 2007 by a Male patient taking Bortezomib (View Usage) (Dosage: B-2.6mg B=d1+4 Iv) was diagnosed with mantle cell lymphoma and. Location: UNITED STATES , 54 years of age, weighting 191.6 lb, After Bortezomib was administered, patient had the following side effects: pulmonary embolism (What is pulmonary embolism?). During the same period patient was treated with CYCLOPHOSPHAMIDE (C=600mg C=d1,2,3 Iv) (View Cyclophosphamide Review and Cyclophosphamide Label ), RITUXAN (View Rituxan Review and Rituxan Label ), DOXORUBICIN HCL (Dox=50mg Dox=d1-2 Civ) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), DEXAMETHASONE (Dex=1-4) (View Dexamethasone Review and Dexamethasone Label ), VINCRISTINE (Vcr=1mg D3 Iv) (View Vincristine Review and Vincristine Label ).

5546752-9 | Febrile Neutropenia, Haemoglobin Abnormal, Platelet Count Abnormal, Rhinitis, Sinusitis
on Dec 07, 2007 Male patient from UNITED STATES , 61 years of age, weighting 203.9 lb, was diagnosed with mantle cell lymphoma and was treated with Bortezomib (View Usage). Patient experienced the following unwanted or unexpected effects: febrile neutropenia, haemoglobin abnormal, platelet count abnormal, rhinitis, sinusitis (What is sinusitis?). Bortezomib dosage: 2.7mg D1+4 Iv. During the same period patient was treated with CYCLOPHOSPHAMIDE (630mg D1,2,3 Iv) (View Cyclophosphamide Review and Cyclophosphamide Label ), RITUXIMAB (90mg Iv D1) (View Rituximab Review and Rituximab Label ), DOXORUBICIN HCL (52mg D1-2 Civ) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), DEXAMETHASONE TAB (40mg Po) (View Dexamethasone Tab Review and Dexamethasone Tab Label ), VINCRISTINE (1mg D3 Iv) (View Vincristine Review and Vincristine Label ). Patient was hospitalized.

5542046-6 | Excessive Granulation Tissue, Osteonecrosis, Tooth Extraction
on Dec 04, 2007 Female patient from TURKEY , 45 years of age, weighting 178.6 lb, was treated with Bortezomib (View Usage). Patient had the following side effects: excessive granulation tissue, osteonecrosis (What is osteonecrosis?), tooth extraction. Bortezomib dosage: . During the same period patient was treated with ZOMETA (4 Mg, Unk) (View Zometa Review and Zometa Label ).

5509922-1 | Nasopharyngitis
Patient was taking Bortezomib (View Usage). After Bortezomib was administered, patient had the following side effects: nasopharyngitis on Nov 07, 2007 from UNITED STATES Additional patient health information: Male patient , 63 years of age, weighting 61.40 lb, . Bortezomib dosage: 1.6 Mg/m2 Days 1+8 Iv. During the same period patient was treated with BEVACIZUMAB (15 Mg/kg Day 1 Iv) (View Bevacizumab Review and Bevacizumab Label ), COLACE (View Colace Review and Colace Label ), NORVASC (View Norvasc Review and Norvasc Label ), GLYBURIDE (View Glyburide Review and Glyburide Label ).

5509747-7 | Furuncle, Perirectal Abscess
Adverse event was reported on Nov 07, 2007 by a Male patient taking Bortezomib (View Usage) (Dosage: 1.3mg/m2 On Days 1 + 4) was diagnosed with mantle cell lymphoma and. Location: UNITED STATES , 70 years of age, weighting 215.2 lb, Patient experienced the following unwanted or unexpected effects: furuncle, perirectal abscess. During the same period patient was treated with RITUXAN (375mg/m2 On Day 1) (View Rituxan Review and Rituxan Label ), ATIVAN (View Ativan Review and Ativan Label ), AUGMENTIN (AMOXICILLIN/CLAV.ACID) (View Augmentin (amoxicillin/clav.acid) Review and Augmentin (amoxicillin/clav.acid) Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), TYLENOL #3 (ACETAMINOPHEN W/CODEINE) (View Tylenol #3 (acetaminophen W/codeine) Review and Tylenol #3 (acetaminophen W/codeine) Label ), ZOFRAN (CHEMO N/V) (ONDANSETRON HCL (CHEMO N/V)) (View Zofran (chemo N/v) (ondansetron Hcl (chemo N/v)) Review and Zofran (chemo N/v) (ondansetron Hcl (chemo N/v)) Label ). Patient was hospitalized.

5506009-9 | Blood Phosphorus Decreased, Chills, Hypotension, Incontinence, Loss Of Consciousness, Pain, Rhabdomyolysis
on Nov 01, 2007 Female patient from UNITED STATES , weighting 158.7 lb, was diagnosed with acute lymphocytic leukaemia and was treated with Bortezomib (View Usage). Patient had the following side effects: blood phosphorus decreased, chills, hypotension, incontinence, loss of consciousness, pain (What is pain?), rhabdomyolysis. Bortezomib dosage: 2.3mg Once Iv. During the same period patient was treated with DOXORUBICIN HCL (107mg Iv Once) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ).

5503966-1 | Abdominal Pain, Adverse Reaction, Asthenia, Blood Potassium Decreased, Discomfort, Dizziness, Gout, Hypokalaemia, Nausea
on Oct 30, 2007 Male patient from UNITED STATES , 58 years of age, was treated with Bortezomib (View Usage). After Bortezomib was administered, patient had the following side effects: abdominal pain (What is abdominal pain?), adverse reaction, asthenia, blood potassium decreased, discomfort, dizziness (What is dizziness?), gout (What is gout?), hypokalaemia, nausea (What is nausea?). Bortezomib dosage: 2.6mg Other Iv. Patient was hospitalized.

5455782-7 | Disease Recurrence, Herpes Zoster
Patient was taking Bortezomib (View Usage). Patient experienced the following unwanted or unexpected effects: disease recurrence, herpes zoster on Sep 13, 2007 from UNITED STATES Additional patient health information: Male patient , weighting 181.3 lb, was diagnosed with multiple myeloma (What is multiple myeloma?) and. Bortezomib dosage: 2.6mg X1 (days 1,4,8,11) Iv Push. During the same period patient was treated with MORPHINE SULFATE (View Morphine Sulfate Review and Morphine Sulfate Label ), CYCLOBENZAPRINE HCL (View Cyclobenzaprine Hcl Review and Cyclobenzaprine Hcl Label ), WARFARIN SODIUM (View Warfarin Sodium Review and Warfarin Sodium Label ), SERTRALINE (View Sertraline Review and Sertraline Label ), SIMVASTATIN (View Simvastatin Review and Simvastatin Label ), CYPROHEPTADINE HCL (View Cyproheptadine Hcl Review and Cyproheptadine Hcl Label ), DOCUSATE (View Docusate Review and Docusate Label ), RANITIDINE (View Ranitidine Review and Ranitidine Label ).

5399138-4 | Atelectasis, Chest Discomfort, Disease Progression, Dyspnoea, Neoplasm Malignant, Pleural Effusion
Adverse event was reported on Jul 25, 2007 by a Female patient taking Bortezomib (View Usage) (Dosage: 0.7 Mg/m2 Iv Day 1, 4, 8,11) was diagnosed with non-small cell lung cancer and. Location: UNITED STATES , weighting 182.5 lb, Patient had the following side effects: atelectasis, chest discomfort, disease progression, dyspnoea, neoplasm malignant, pleural effusion. During the same period patient was treated with CARBOPLATIN (Auc=6 Iv Q21 Days) (View Carboplatin Review and Carboplatin Label ), DOCETAXEL (60 Mg/m2 Iv Q21 Days) (View Docetaxel Review and Docetaxel Label ), MOTRIN (View Motrin Review and Motrin Label ), VICODIN (View Vicodin Review and Vicodin Label ), COMPAZINE (View Compazine Review and Compazine Label ), DECADRON (View Decadron Review and Decadron Label ), KYTRIL (View Kytril Review and Kytril Label ), ZOFRAN (View Zofran Review and Zofran Label ). Patient was hospitalized.

5393395-6 | Atelectasis, Pleural Effusion
on Jul 17, 2007 Female patient from UNITED STATES , weighting 182.5 lb, was diagnosed with non-small cell lung cancer and was treated with Bortezomib (View Usage). After Bortezomib was administered, patient had the following side effects: atelectasis, pleural effusion. Bortezomib dosage: 0.7 Mg/m2 Iv Day 1,4,8,11. During the same period patient was treated with CARBOPLATIN (Auc 6 Iv Q21 Days) (View Carboplatin Review and Carboplatin Label ), DOCETAXEL (60 Mg/m2 Iv Q21 Days) (View Docetaxel Review and Docetaxel Label ), MOTRIN (View Motrin Review and Motrin Label ), DECADRON (View Decadron Review and Decadron Label ), VICODIN (View Vicodin Review and Vicodin Label ), KYTRIL (View Kytril Review and Kytril Label ), COMPAZINE (View Compazine Review and Compazine Label ), ZOFRAN (View Zofran Review and Zofran Label ). Patient was hospitalized.

5389398-8 | Chills, Febrile Neutropenia, Leukopenia, Malaise, Pain In Jaw
on Jul 13, 2007 Male patient from UNITED STATES , 57 years of age, weighting 230.0 lb, was diagnosed with mantle cell lymphoma and was treated with Bortezomib (View Usage). Patient experienced the following unwanted or unexpected effects: chills, febrile neutropenia, leukopenia, malaise, pain in jaw. Bortezomib dosage: 2.9mg Day 1+4 Iv. During the same period patient was treated with CYCLOPHOSPHAMIDE (660mg 6dose Iv) (View Cyclophosphamide Review and Cyclophosphamide Label ), RITUXIMAB 125MG IV DAY (View Rituximab 125mg Iv Day Review and Rituximab 125mg Iv Day Label ), DOXORUBICIN HCL (55mg Day1-2 Civ) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), DEXAMETHASONE 0.5MG TAB (40mg 4d Po) (View Dexamethasone 0.5mg Tab Review and Dexamethasone 0.5mg Tab Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ). Patient was hospitalized.

5345329-8 | Diarrhoea, Hypotension
Patient was taking Bortezomib (View Usage). Patient had the following side effects: diarrhoea, hypotension on Jun 01, 2007 from UNITED STATES Additional patient health information: Female patient , 60 years of age, weighting 111.0 lb, was diagnosed with squamous cell carcinoma and. Bortezomib dosage: 1.6mg/m2 Iv Days 1+8. During the same period patient was treated with DOCETAXEL (40mg/m2 Day 8) (View Docetaxel Review and Docetaxel Label ), PREVACID (View Prevacid Review and Prevacid Label ), PREMARIN (View Premarin Review and Premarin Label ), SYNTHROID (View Synthroid Review and Synthroid Label ), LEXAPRO (View Lexapro Review and Lexapro Label ), MEGACE (View Megace Review and Megace Label ), PHENERGAN HCL (View Phenergan Hcl Review and Phenergan Hcl Label ), KYTRIL (View Kytril Review and Kytril Label ). Patient was hospitalized.